CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for CEL-SCI Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

CEL-SCI Corp
SUITE 802, 8229 BOONE BLVD .
Phone: (703) 506-9460p:703 506-9460 VIENNA, VA  22182  United States Ticker: CVMCVM

Business Summary
CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers, and Ligand Epitope Antigen Presentation System (LEAPS), with several product candidates under development for the potential treatment of rheumatoid arthritis. Multikine is a biological medicinal immunotherapy comprising a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment before the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikines rationale for use is to incite a locoregional immune response against the tumor.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20239/30/2023YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Executive Officer, Chief Financial Officer, Treasurer, Director Geert R.Kersten 65 2/1/1995 2/1/1995
Senior Vice President - Operations, Corporate Secretary Patricia B.Prichep 73 5/1/2000 3/1/1994
Senior Vice President - Regulatory Affairs JohnCipriano 82 10/1/2009 3/1/2004
6 additional Officers and Directors records available in full report.

Business Names
Business Name
CVM
Viral Technologies, Inc.

General Information
Number of Employees: 43 (As of 11/30/2011)
Outstanding Shares: 53,979,231 (As of 2/8/2024)
Shareholders: 500
Stock Exchange: ASE
Federal Tax Id: 840916344
Fax Number: (703) 506-9471


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024